References
- Nielsen SE, Nielsen OH, Vainer B, Claesson MH. Inflammatory bowel disease: do microorganisms play a role?. Ugeskr Laeger 2002; 164: 5947–50
- Steinhart AH, Girgrah N, McLeod RS. Reliability of a Crohn's disease clinical classification scheme based on disease behavior. Inflamm Bowel Dis 1998; 4: 228–34
- Sachar D, Andrews H, Farmer RG, Pallone F, Pena A, Prantera Crutgeerts P. Proposed classification of patient subgroups in Crohn's disease. Gastro Int 1992; 5: 141–54
- Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer S, Irvine E, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8–15
- Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002; 122: 854–66
- Duerr RH. Update on the genetics of inflammatory bowel disease. J Clin Gastroenterol 2003; 37: 358–67
- Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zann A, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004; 127: 26–40
- Li J, Moran T, Swanson E, Julian C, Harris J, Bonen DK, et al. Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet 2004; 13: 1715–25
- Dooley TP, Curto EV, Reddy SP, Davis RL, Lambert GW, Wilborn TW, et al. Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs: screening by DNA microarrays. Inflamm Bowel Dis 2004; 10: 1–14
- Uthoff SM, Eichenberger MR, Lewis RK, Fox MP, Hamilton CJ, McAuliffe TL, et al. Identification of candidate genes in ulcerative colitis and Crohn's disease using cDNA array technology. Int J Oncol 2001; 19: 803–10
- Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 2001; 10: 445–56
- Dieckgraefe BK, Stenson WF, Korzenik JR, Swanson PE, Harrington CA. Analysis of mucosal gene expression in inflammatory bowel disease by parallel oligonucleotide arrays. Physiol Genomics 2000; 4: 1–11
- Fukushima K, Ogawa H, Takahashi K, Naito H, Funayama Y, Kitayama T, et al. Non-pathogenic bacteria modulate colonic epithelial gene expression in germ-free mice. Scand J Gastroenterol 2003; 38: 626–34
- Csillag C, Nielsen OH, Borup R, Nielsen FC. Microarrays and Crohn's disease: Collecting reliable information. Scand J Gastroenterol 2005; 40: 369–377
- Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, et al. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev 2003; 12: 755–62
- Distler P, Holt PR. Are right- and left-sided colon neoplasms distinct tumors?. Dig Dis 1997; 15: 302–11
- Munkholm P, Langholz E, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962–87: a sixfold increase in incidence. Scand J Gastroenterol 1992; 27: 609–14
- Munkholm P, Binder V. Clinical features and natural history of Crohn's disease. Kirsner's inflammatory bowel diseases, RB Sartor, WJ Sandborn. Saunders, Philadelphia 2004; 754
- Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360–2
- Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334: 841–8
- Wei C, Li J, Bumgarner RE. Sample size for detecting differentially expressed genes in microarray experiments. BMC Genomics 2004; 5: 87
- Day D, Jass J, Price A, Shepherd N, Sloan J, Talbot I, et al. Morson and Dawson's gastrointestinal pathology. 4th ed. Blackwell Science, OxfordUK 2003; 505–7
- Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993; 15: 532–7
- Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001; 98: 31–6
- Cope LM, Irizarry RA, Jaffee HA, Wu Z, Speed TP. A benchmark for Affymetrix GeneChip expression measures. Bioinformatics 2004; 20: 323–31
- PDCD6. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601057.
- Lee JH, Rho SB, Chun T. Programmed cell death 6 (PDCD6) protein interacts with death-associated protein kinase 1 (DAPk1): additive effect on apoptosis via caspase-3 dependent pathway. Biotechnol Lett 2005; 27: 1011–5
- ATN1. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=607462.
- DAPP1. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=605768.
- Csillag C, Nielsen OH, Vainer B, Olsen J, Dieckgraefe BK, Hendel J, et al. Expression of the genes dual oxidase 2, lipocalin 2 and regenerating islet-derived 1 alpha in Crohn's disease. Scand J Gastroenterol 2006; 41
- Pickard KM, Bremner AR, Gordon JN, MacDonald TT. Microbial-gut interactions in health and disease. Immune responses. Best Pract Res Clin Gastroenterol 2004; 18: 271–85
- Sansonetti PJ. War and peace at mucosal surfaces. Nat Rev Immunol 2004; 4: 953–64
- Lennard L, Lilleyman JS. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monit 1996; 18: 328–34
- Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnet D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705–13
- Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115: 813–21
- Connell WR, Kamm MA, Ritchie JK, Lennart-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081–5
- Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BJ. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641–9